A family of cytokine-inducible SH2 proteins (CISs) has recently been identified and the number of family members is growing. In this family, the central SH2 domain and C-terminal (about 40 amino acids) (CIS homology domain; CH domain) are well conserved, while N-terminal region shares little similarity and varies in length. Most of them appear to be induced after stimulation with several different cytokines and at least three of them (CIS1, CIS3 and JAB) negatively regulate cytokine signal transduction by various means. Forced expression of CIS1 inhibits STAT5 activation by binding to cytokine receptors, whereas CIS3 and JAB directly binds to the kinase domain of JAKs, thereby inhibiting tyrosine kinase activity. Therefore, these CIS family members seem to function in a classical negative feedback loop of cytokine signaling. They may also be involved in suppression between cytokines frequently found in immune and inflammatory responses. JAB is found to inhibit interferon signaling, suggesting that elevated expression of JAB is involved in interferon-resistance. The mechanisms by which these inhibitors of cytokine signal transduction exert their effects and their physiological functions are crucial issues which need to be and will be addressed in the near future.
Introduction
Growth, differentiation and other functions of immune and hematopoietic cells are controlled by multiple cytokines, including interleukins (ILs) and colony-stimulating factors. Although lacking catalytic domains, members of the cytokine receptor superfamily mediate ligand-dependent activation of protein tyrosine phosphorylation through their association and activation of members of the Janus kinase (JAK) family of protein tyrosine kinases. 1, 2 Cytokines induce homo-dimerization and activation of their cognate receptors, resulting in the activation of associated JAK kinases (JAK1, JAK2, JAK3 and Tyk2). The activated JAKs phosphorylate the receptor cytoplasmic domains which creates docking sites for SH2-containing signaling proteins. Among the substrates of tyrosine phosphorylation are members of the signal transducers and activators of the transcription family of proteins (STATs). 3, 4 Although this pathway was found initially to be activated by interferons (IFNs), it is now known that a large number of cytokines, growth factors and hormonal factors activate JAK and/or STAT proteins. Various cytokines induce the tyrosine phosphorylation and activation of one or more of the seven STAT family members.
The role of various STATs in the biological responses to cytokines has been assessed through the analysis of receptor Correspondence: A Yoshimura; Fax: 81 942 31 5212 Received 8 September 1998; accepted 16 September 1998 mutations which disrupt STAT activation and more recently by disruption of the genes in mice. For example, mice in which the genes for STAT1, STAT4 and STAT6 are disrupted are viable but lack functions that are mediated by interferons, interleukin 12 (IL-12) or IL-4, respectively, [5] [6] [7] [8] [9] suggesting that these STATs perform very specific functions in immune responses. In contrast, the two highly related STAT5a and STAT5b are activated by various cytokines, including growth hormone (GH), prolactin (PRL), erythropoietin (EPO), interleukin-2 (IL2), IL3, granulocyte-macrophage colony-stimulating factor (GM-CSF) and thrombopoietin (TPO). Phenotype of STAT5a and b single gene knockout mice, as well as double knockout mice revealed that an important role of STAT5s in PRL and GH signaling, as well as in IL2-dependent T cell functions. [10] [11] [12] [13] Over the years, the majority of investigations on cytokines have focused on the mechanisms by which they exert their actions. However, it is clear that the actions of cytokines are limited in both magnitude and duration, making it important to understand the mechanisms by which their actions are negatively controlled. Moreover, down-modulation of one cytokine action by several factors including another cytokine are often found in important physiological circumstances. For example, Th1 and Th2 cytokines suppress each other. 14 cAMP, calcium ionophore, and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been shown to inhibit JAK1-STAT1 or STAT3 pathways, 15 although the molecular basis of such modulation has not been well characterized. Deregulation of negative feedback of the JAK-STAT pathway has been implicated in hematopoietic disorders, autoimmune and inflammatory diseases, interferon (IFN)-resistance and cancer. For example, constitutive activation of JAK and/or STATs has been implicated in transformation by vsrc. 16, 17 A constitutively active TEL-JAK fusion gene is implicated in T cell leukemia. 18, 19 Mutations in the erythropoietin (EPO) receptor gene causing deletion of the C-terminal region have been implicated in familial erythrocytosis and is inherited as an autosomal dominant trait. 20 In this disease, disruption of SHP-1 binding sites of the EPO receptor at the Cterminal region has been shown to cause prolonged activation (phosphorylation) of JAK2. 21 In Table 1 , the major regulatory mechanisms of JAK-STAT pathways are listed. Degradation of STATs and receptors should be involved in regulation of signaling. 22, 23 Naturally occurring dominant negative variants of STAT5 were also reported. 24, 25 A specific STAT3 inhibitor, PIAS3 has also been reported, however, its physiological meaning has not been clarified. 26 Tyrosine phosphatases, containing the SH2 domain, also regulate cytokine signaling, both positively and negatively. Recently, a new family of cytokine-inducible SH2 proteins (CISs) that in turn inhibit cytokine action have been watched with keen interest. Some of the members have been shown to be involved in negative regulation of cytokine signals, especially JAKs and STATs.
CIS: prototype of cytokine-induced SH2 proteins
The first member of this family was denoted as CIS (now called as CIS1), for cytokine-induced SH2 containing protein. 27 ,28 CIS1 was cloned originally as an immediate-early gene that was induced by IL-2, IL-3 and EPO. CIS1 was found to associate with the tyrosine phosphorylated EPO receptor and the IL-3 receptor ␤ chain following stimulation with EPO of IL-3, respectively. 27 Recently, we also found that CIS1 binds to PRL receptor and IL2 receptor ␤ chain (W Doppeler et al, and M Javad Aman et al, manuscripts in preparation). From a functional perspective, it was noted that forced expression of CIS1 could partially suppress IL-3-induced proliferation, although the mechanism of action of CIS1 was unclear. 27 One possibility is that CIS1 is an adaptor protein (between cytokine receptors and other molecules involved in growth inhibition) based on the presence of an SH2 domain in the central portion of the molecule and both N-and C-terminal regions that are rich in proline and leucines, residues that can be involved in mediating protein-protein interactions. Alternatively, it was also suggested that CIS1 might function by directly blocking phosphotyrosine motifs on receptors, preventing their coupling to stimulatory signaling pathways. 27 Finally, given that CIS1 was observed to have a relatively short half-life, a third potential role that was suggested was that CIS1 might be a scavenger of tyrosine phosphorylated proteins, targeting them for degradation as well. 27 We have recently found that CIS1 is ubiquitinated. 29 Thus, it is possible that CIS1 is involved in ubiquitine/proteasome dependent degradation of the activated cytokine receptors.
The CIS1 promoter contains two pairs of tandem TTCNNNGAA motifs that are capable of binding Stat5, and a CIS1 promoter reporter construct was induced by EPO in cells transfected with EPOR and Stat5. 30 The essential role of STAT5 in CIS1 expression was confirmed by the observation that CIS1 expression was not observed in ovaries of STAT5ab-double KO mice. 13 In addition to the production of CIS1 being regulated by the Jak-Stat5 pathway, it was interesting that CIS1 could negatively modulate Stat5 activation; 30 forced expression of CIS1 partially suppressed STAT5 activation in 293T and Ba/F3 cells. Thus, CIS1 acts as a kind of negative feedback regulator of the JAK-STAT5 pathway. The negative effects of CIS1 on STAT5 expression were confirmed by the recent observations in CIS1-transgenic mice (Matsumoto et al, manuscript in preparation). The female transgenic mice did not produce enough milk, therefore they could not feed pups, suggesting defects in PRL/STAT5 signaling. The mice also exhibited growth retardation, as well as defects of IL2-response in T cells, which were similarly observed in STAT5a or STAT5b or double KO mice (Matsumoto et al, manuscript in preparation). Therefore, it is now clear that CIS1 is a negative regulator of STAT5, at least when it is overexpressed. The crucial molecular mechanisms of inhibition should be elucidated in the near future.
Identification of JAB/SOCS-1/SSI-1
Three groups, including us independently cloned the second CIS family member by entirely different experimental approaches. Starr et al 31 cloned suppresser of cytokine signaling-1 (SOCS-1) as an inhibitor of IL-6-induced differentiation and growth arrest of the murine monocytic leukemia cell line M1. Endo et al 32 cloned the same protein as a JAKbinding protein (JAB) that could interact with the catalytic (JH1) domain of JAK2 and Naka et al 33 identified it using an antibody that recognizes a common sequence of SH2 domain of STATs and that it was not a STAT protein but instead was STAT-induced STAT inhibitor-1 (SSI-1). Collectively, JAB/SSI-1/SOCS-1 is a potent inhibitor of IL-6 signaling, including IL-6-induced tyrosine phosphorylation of gp130 and STAT3. Interestingly, JAB can interact with not only JAK2 but also with JAK1 and Tyk2, and is an inhibitor of JAK catalytic activity. When it is overexpressed, JAB can inhibit any signaling utilizing JAKs, such as STAT5 activation by EPO, STAT3 activation by leukemia inhibitory factor (LIF) or IL6, and c-fos induction by IL2. However, since JAB did not inhibit fibroblast growth factor (FGF) signaling, although it binds to the FGF receptor, it seems to be specific to JAK tyrosine kinases. 34 Ohya et al 35 also cloned the same gene (called TIP-3) by two-hybrid screening using Tec kinase domain as bait. JAB was found to suppress Tec kinase activity, however, this effect was marginal compared with JAKs. Again, it is notable that binding does not always mean inhibition.
The CIS family
By the database search, Masuhara et al 34 reported an additional five CIS family members (CIS2-6). Hilton's group 36 also identified one additional member (SOCS-7/CIS7; partial cDNA). A partial cDNA of CIS5 was also cloned by Takenawa's group as a binding protein for the SH3 domains of Nck, Ash/Grb2, phospholipase-C (PLC)␥. 37 This gene was expressed mainly in the brain. Others are expressed in hematopoietic and lymphoid tissues such as bone marrow, spleen, and thymus, and their expression is induced by a subset of cytokines in some hematopoietic cells. 34 Thus, it is reasonable that this family is called the CIS family. Notably, CIS3 is shown to be induced by growth hormone and leptin, 38, 39 and is also induced by TNF and IL1, which do not normally use JAK/STATs. 31 CIS3 is also expressed in the murine pituitary in vivo and injection of LIF or interleukin-1 beta pituitary CIS3 mRNA was stimulated nine-fold and six-fold, respectively. 39 Figure 1 shows alignment of the predicted amino acid sequences of human CIS family members (CISs). While the N-terminal regions share little sequence similarity, all seven contain SH2 domain and a conserved C-terminal region that we designate as the CH (CIS-homology) domain. The consensus motif in the CH domain is LXXPXXRX 5 SLQHLCRXXI-X 6-9 IXXLPLPXXLXDYLXXYXY/F (X; any amino acid), although the entire length of the C-terminal region was varied. The SH2 domain exhibits 23-58% identity among CISs. Relatively high identity was seen between CIS1 and CIS2 (about 50%), CIS4 and CIS5 (about 58%), and JAB and CIS3 (about 40%). The first three amino acids of the SH2 domain of JAB and CIS3 are FYW, whereas those of other CISs are WYW, suggesting that the first residue, F, may be important for binding of JAB and CIS3 to JAK kinases (see below). The -5 and -1 positions of the SH2 domain are fixed as L and G, respectively. Interestingly, SH2 domains of STATs also contain the same amino acids at these positions. 40 The N-terminal region is only 40-80 amino acids in length except for CIS4-7 which have quite a long N-terminal region (more than 350 amino acids).
Figure 1
Amino acid sequence alignments of the seven human CIS family genes. Black boxes indicate positions at which at least four amino acids are identical, and gray boxes indicate those at which three amino acids are identical. The partial amino acid sequences available for CIS5/NAP4. Table 1 Regulatory mechanism of JAK-STAT pathway 
CH-domain-containing proteins
Database search also revealed that a similar CH domain is present in several proteins which contain ankyrin-like repeats, in the Ras-like GTPases and in proteins containing WD domain. 29 Hilton's group call this domain the SOCS box. 36 They have identified a further 16 proteins that contain this motif by using a database search. These proteins fall into five classes based on the protein motifs found N-terminal of the CH domain. In addition to four new CIS proteins (SOCS-4 to SOCS-7) containing an SH2 domain, they describe four new families of proteins that contain either WD-40 repeats (WSB-1 and -2), SPRY domains (SSB-1 to -3), or ankyrin repeats (ASB-1 to -3), as well as G proteins. Although the function of these protein families remains to be determined, CH domain may be involved in signal transduction because these domains in the N-terminal region are frequently found in signaling molecules.
Nomenclature
Since CIS was the first member of this family to be identified, and most of the family members are cytokine-inducible genes, we have referred to these proteins as the CIS family proteins. SOCS, JAB, and SSI nomenclatures all have merit, but the sooner that nomenclature can be agreed upon, the greater will be the clarity for the scientific community to understand the multiple studies that are likely to be published related to this exciting family of molecules. In Table 1 , different names of each CIS member are listed. 
Binding of CIS3 and JAB to JAK2 tyrosine kinase domain and their inhibitory effect on JAK signaling
Among CIS family members, only CIS3 and JAB can bind to JAK2-JH1. 34, 41 Binding was confirmed by using two-hybrid analysis, as well as co-precipitation assay in vitro and in vivo. Interaction of JAK2-JH1 with JAB was stronger than that with CIS3.
By using a simple reporter gene assay system, we found that JAB and CIS3 almost completely blocked cytokine-dependent STAT3 and STAT5 reporter gene activation. 34 CIS2 and CIS4 had no effect, or rather enhanced the reporter gene activation. However, CIS3 and JAB did not affect FGF-or PDGF-induced c-fos promoter activation, suggesting that the effect of CIS3 and JAB is quite specific to JAK tyrosine kinases. 34 In stable cell lines, CIS3 and JAB can also inhibit the JAK-STAT pathway, however, these two seem to have different activity. Forced expression of CIS3 and JAB in M1 leukemia cells prevented IL6-or LIF-induced growth arrest and differentiation. However, unlike JAB, CIS3 did not inhibit IFN␥-induced growth arrest, suggesting a difference in cytokine specificity between CIS3 and JAB. CIS3 inhibited STAT3 activation with slower kinetics than JAB and allowed rapid c-fos induction and partial Fc␥RI expression in response to IL6, while JAB inhibited STAT3 activation rapidly and profoundly. In JAB transformants, IFN␥-induced STAT1 activation was almost completely suppressed, while it was not affected in CIS3 transformants. These different effects of JAB and CIS3 on cytokine response in M1 cells could be explained by different inhibitory effects of JAB and CIS3 (see below). Minamoto et al 42 reported that overexpression of SSI-2 (CIS2) also conferred resistance to IL6 on M1 cells. However, we and another group obtained differing results (Ref. 34, Hilton et al, personal communication) . These contradictory results should be resolved in the near future.
Tyrosine phosphorylation of JAKs in response to cytokines in M1 cells was not very evident, probably because of very low content of JAKs or receptors. So, we created stable JAB transformants from NIH3T3 cells, and these transformants were defective in IFN␥ and IFN␤ signaling. IFN␥-induced activation of JAK1 and JAK2, as well as IFN␤-induced activation of JAK1 and Tyk2 were clearly detected in NIH-3T3 cells. In contrast, tyrosine phosphorylation of JAK1, JAK2 and Tyk2 was largely impaired in JAB transformants. This was the first example showing that JAB can directly inhibit JAKs in stable cell lines. FGF induced tyrosine phosphorylation and activation of the FGF receptor normally, suggesting that the inhibition of tyrosine kinase activity in JAB transformants was specific to JAKs. Thus, the IFN-unresponsiveness of JAB transformants can be explained by inhibition of activation of JAKs by JAB.
Involvement of JAB in interferon resistance
IFN␥ is the most potent inducer of JAB in a wide variety of cell lines. 41, 42 IFN␤ has no inducible effect. The promoter region of JAB contains potential GAS motifs, 43 suggesting the involvement of STAT1 in the induction of JAB by IFN␥. Previously, JAB was reported to be induced by IL6 in mouse liver and M1 cells, suggesting that JAB is a negative feedback regulator of IL6/STAT3. 31, 33 However, our and others experiments suggest that IL6 or LIF induces expression of JAB much less efficiently than IFN␥. JAB could be a negative feedback regu-lator of IFN␥/STAT1 rather than IL6/STAT3. JAB could be a negative feedback regulator of IFN␥.
Our recent study suggests dysregulated overexpression of JAB can confer IFN-resistance on cells. 44 NIH-3T3 cells ectopically expressing JAB but not CIS3 lost responsiveness to the antiviral effect of IFN␤ and IFN␥. M1 leukemic cells stably expressing JAB were also resistant to IFN␥ and IFN␤-induced growth arrest. In both NIH-3T3 and M1 transformants expressing JAB, IFN␥ did not induce tyrosine phosphorylation and DNA-binding activity of STAT1. We also found that IFNresistant clones derived from LoVo cells and Daudi cells expressed high levels of JAB without stimulation. In IFN-resistant LoVo and Daudi cells, IFN-induced STAT1 and JAK phosphorylation was partially reduced. Therefore, overexpression of JAB could be, at least in part, a mechanism of IFN-resistance with dominant phenotype. IFN-resistance with recessive phenotype has been well described. Mutations in the receptors, JAKs and STATs have been found in IFN-resistant mutants. 44 Reduced activation of JAKs by JAB overexpression could also be, at least in part, a mechanism of IFN-resistance with dominant phenotype. It is clinically important to address whether JAB is involved in the interferon-resistance frequently found in patients with clonic myelogenous leukemia or those carrying hepatitis type C virus.
Physiological function of JAB and CIS3
Since CIS1, CIS3 and JAB are induced by cytokines and negatively regulate cytokine signals, these genes act in a classic negative loop for cytokine signal transduction (Figure 2) . The genes could also be involved in cross-talk among cytokine signals. CISs induced by one cytokine can modulate the intensity of other cytokine signals. For example, GM-CSF inhibits IL6-or IFN␥-dependent STATs activation in monocytic cells.
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Figure 2
Signaling pathways activated in response to cytokines and action of CIS family members. A schematic structure of the cytokine receptor dimer after ligand binding is shown. The bold lines in the cytoplasmic domain of the receptor represent boxes 1 and 2, which share homology among cytokine receptors. Two major signaling pathways, Ras-MAP kinase and JAK-STAT are activated through cytokine receptors. CIS1 binds to the receptor and CIS3 and JAB bind to JAKs, thereby inhibiting signaling.
This inhibition requires new RNA and protein synthesis, thus, CIS family members are good candidates for the factor that contributes to the inhibition.
CIS3 may also act as a negative feedback mediator of the cytokine-mediated neuro-immuno-endocrine interface. Bjorbaek et al 38 found that peripheral leptin administration to ob/ob, but not db/db mice, rapidly induced CIS3 mRNA in hypothalamus, but had no effect on CIS1, JAB, or CIS2. In mammalian cell lines, CIS3, but not CIS1 or CIS2, blocked leptin-induced signal transduction. Expression of CIS3 mRNA in the arcuate and dorsomedial hypothalamic nuclei is increased in Ay/a mice, a model of leptin-resistant murine obesity. CIS3 may be a leptin-inducible inhibitor of leptin signaling, and a potential mediator of leptin resistance in obesity. Auernhammer et al 39 also found that injection of LIF or IL1␤ increased CIS3 mRNA in the pituitary, and in AtT-20 cells, stable overexpression of CIS3 inhibits basal and LIF-stimulated ACTH secretion.
IFN␥ is known as an inhibitory cytokine, and suppresses many cytokine actions and cellular responses. For example, IL4-induced IgE synthesis and germline ⑀ transcription was suppressed in the presence of IFN␥ in B cells. 45 JAB could be a part of the mechanism of the antagonistic effect of IFN␥ on other cytokines. JAB is also most abundantly expressed in the thymus, 31 which suggests a regulatory role for JAB in cytokine actions in T cells. IFN␥ has been shown to play an important role in immune responses, including the development of Th1 cells. 46 IFN␥-treated Th1 cells become resistant to growth inhibition by IFNs, which has been explained by loss of the IFN␥ receptor ␤ chain. 47 However, such loss of the receptor may need long-term incubation of cells with IFN␥. Induction of JAB may partly explain early down-regulation of IFN␥-responsiveness in Th1 cells.
Conclusions
We characterized three of the CIS family members: CIS1, JAB and CIS3. CIS1 is induced via STAT5, then binds to the activated receptor, thereby somehow inhibiting STAT5 activity. JAB and CIS3 are induced by several cytokines (probably either STAT1 or STAT3 is involved in this induction), then bind to JAK kinases directly, thereby inhibiting kinase activity. Although little is known about other CIS family members, study of their physiological functions has been started. Understanding the mechanisms by which JAKs and STATs are inhibited by CISs are very important for developing specific pharmacological inhibitors of cytokine signaling, as well as tyrosine kinases. In addition to the need to further understand their mechanism(s) of action of these CIS/JAB protein, it remains unclear to what degree these proteins have overlapping vs distinct functions. The preparation of knockout mice in which each of these molecules is individually deleted, as well as knockout mice in which combinations of these proteins are deleted, should help to clarify the distinctive functions of each of these proteins.
